Compare JZXN & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JZXN | AEMD |
|---|---|---|
| Founded | 2019 | 1984 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 2.1M |
| IPO Year | 2020 | 2008 |
| Metric | JZXN | AEMD |
|---|---|---|
| Price | $1.49 | $3.03 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 2.0M | 133.0K |
| Earning Date | 02-24-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.12 | $0.51 |
| 52 Week High | $8.50 | $5.89 |
| Indicator | JZXN | AEMD |
|---|---|---|
| Relative Strength Index (RSI) | 53.56 | 76.28 |
| Support Level | $0.95 | $2.00 |
| Resistance Level | $1.96 | $3.22 |
| Average True Range (ATR) | 0.18 | 0.18 |
| MACD | 0.01 | 0.30 |
| Stochastic Oscillator | 41.56 | 80.21 |
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It is into trade business with a focus on sales of new energy batteries including design, commissioned processing, transportation and packaging, sales of electrical equipment, mobile phone accessories and other products. Its revenues consist of two reportable operating segments: (i) Sales of new energy batteries, including production, transportation, and packaging, in the mainland Pearl River Delta region; and(ii) Sales and production of electric vehicles in Southeast Asia, including two-wheelers, three-wheeled electric scooters, and slow-speed vehicles.
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.